Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00096473 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease

A Phase 3 study of Dementia and Alzheimers Disease, sponsored by Eisai.

Completed
Registry status
Phase 3
Development phase
229
Enrollment target
20
Study locations

NCT00096473 is a Phase 3 study of Dementia and Alzheimers Disease that has completed, run by Eisai. The registered enrollment target is 229 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00096473, a Phase 3 study of Dementia and Alzheimers Disease, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 3
Development phase
229 participants
Enrollment target
20
Study locations

Study Summary

Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer's disease. Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better.

Conditions Studied

Dementia Alzheimers Disease

Interventions

  • DRUG Donepezil hydrochloride

Study Locations (20)

Florida

  • - Fort Lauderdale
  • - Fort Myers
  • - North Miami
  • - St. Petersburg

Arizona

  • - Phoenix
  • - Sun City
  • - Tucson

California

  • - San Francisco
  • - Santa Monica
  • - Torrance

New Jersey

  • - Long Branch
  • - Piscataway

Alabama

  • - Northport

Colorado

  • - Denver

Georgia

  • - Atlanta

Illinois

  • - Chicago

Trial Details

FieldValue
Enrollment Target 229 participants
Start Date 2001-01
Est. Completion 2005-09
Phase Phase 3

Sponsor

Eisai

287 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00096473

The ClinicalTrials.gov registry entry for NCT00096473 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (97% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 1 intervention - of which Donepezil hydrochloride is the first listed.

NCT00096473 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT00096473 about?

NCT00096473 is a clinical study titled "Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease". Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further inv...

What is the current status of trial NCT00096473?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 229 participants. The study started on 2001-01. Estimated completion is 2005-09.

What conditions does trial NCT00096473 study?

This clinical trial studies the following conditions: Dementia, Alzheimers Disease.

What interventions are being tested in trial NCT00096473?

The interventions under investigation include: Donepezil hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00096473?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00096473 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dementia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dementia

All registered trials for this condition

Alzheimers Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.